Harpoon Therapeutics (HARP: NASDAQ) Investor Relations Material

Overview

Harpoon Therapeutics Inc., a clinical-stage immunotherapy company based in South San Francisco, is at the forefront of a groundbreaking pursuit to develop a new class of T cell engagers. Utilizing this innovative platform, the company aims to tap into the body's natural immune system to effectively treat cancer and other diseases. Harpoon's product candidate, the tri-specific T cell activating construct, or TriTAC, includes two promising drugs in the clinical trial phase. The HPN328 is currently undergoing Phase I and II trials to combat small cell lung cancer and tumors expressing Delta-like canonical Notch ligand 3, while the HPN217 is undergoing Phase I trials for multiple myeloma. Harpoon also boasts a preclinical stage product, the HPN601, designed to address multiple solid tumor indications. The company has secured a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and market products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics was established in 2015 and seeks to revolutionize immunotherapy in the United States.